Soligenix to Initiate Phase 3 Trial of HyBryte for Cutaneous T Cell Lymphoma
核心洞察
Soligenix is set to begin a Phase 3 trial (FLASH2) of HyBryte for cutaneous T cell lymphoma (搜索) (CTCL (搜索)) treatment before the end of 2024, mirroring the design of the previous FLASH trial.
Recent data presented at EORTC highlighted HyBryte's effectiveness and favorable safety profile compared to Valchlor in treating CTCL (搜索), alongside minimal systemic exposure.
Soligenix has partnered with Sterling Pharma Solutions (搜索) to enhance the manufacturing process for synthetic hypericin, aiming to reduce production costs for HyBryte.
Soligenix, Inc. is on track to commence a confirmatory Phase 3 clinical trial, named FLASH2, evaluating HyBryte for the treatment of cutaneous T cell lymphoma (搜索) (CTCL (搜索)) before the close of 2024. This trial is designed to closely replicate the structure of the previous Phase 3 FLASH trial, a strategic decision aimed at bolstering confidence in achieving positive outcomes.
With patient enrollment slated to begin before the end of 2024, Soligenix anticipates topline results from the FLASH2 trial will be available in the second half of 2026. Following an agreement with the European Medicines Agency (EMA) on key design aspects, Soligenix is in ongoing discussions with the U.S. Food and Drug Administration (FDA) to finalize the study design. The FDA has expressed interest in a longer duration comparative study rather than a placebo-controlled trial.
Supportive Data Presented at EORTC
In October 2023, Soligenix presented findings from additional supportive trials of HyBryte at the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumor Group Annual Meeting. These presentations included an oral presentation by Dr. Brian Poligone, which highlighted results from two expanded treatment studies. The HPN-CTCL (搜索)-02 study demonstrated minimal systemic exposure to hypericin following topical application. The HPN-CTCL-04 study indicated that HyBryte treatment was more effective than Valchlor with a more favorable safety profile.
Dr. Ellen Kim presented a poster on an investigator-initiated study examining longer treatment durations with hypericin in CTCL (搜索). Early results from this study, involving patients treated for at least 18 weeks, showed a 75% index lesion response rate, defined as a ≥50% reduction in mCAILS score of index lesions from baseline to the end of treatment. No serious adverse events were reported.
Hypericin Production Partnership
Soligenix announced a partnership with Sterling Pharma Solutions (搜索) in October 2024 to develop a scalable production technology for synthetic hypericin, the active pharmaceutical ingredient in HyBryte. This collaboration aims to optimize manufacturing processes to enable GMP manufacturing and reduce overall production costs as Soligenix advances toward potential commercialization.
Financial Position
As of November 9, 2024, Soligenix reported having approximately $9.8 million in cash and cash equivalents. The company's financial strategy is focused on supporting the clinical development of HyBryte and other pipeline assets.